Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT06780293 Sponsor: Taipei Veterans General Hospital, Taiwan Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT06780293
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the Dry Eye Syndrome group:

  • People aged between 20 and 75 years
  • People whose Schirmer's test result (a test that measures how much moisture the eye produces) shows less than 10 mm of fluid in 5 minutes, indicating low tear production

For the Sjögren's Syndrome group:

  • People aged between 20 and 75 years
  • People diagnosed with either primary or secondary Sjögren's syndrome
  • People whose condition meets the 2002 American-European Consensus Criteria for Sjögren's syndrome (a recognised set of diagnostic standards)
  • People whose immune system, liver, kidney, and blood function test results are all within normal ranges

Who may not be able to join:

For the Dry Eye Syndrome group:

  • People who are pregnant
  • People who currently have eye inflammation or an infectious eye disease
  • People who have previously had eye surgery

For the Sjögren's Syndrome group:

  • People with a history of alcohol abuse, diabetes, or a serious life-threatening medical condition
  • People who are pregnant or breastfeeding
  • People who have received steroid pulse therapy (a high-dose steroid treatment) within the three months before the trial begins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886-28757453, 333

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Taipei Veterans General Hospital, Taiwan
Registry
ClinicalTrials.gov
Start date
3 February 2025
Est. completion
30 April 2025

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Numerical Rating Scale (NRS); Schirmer's test; Ocular Surface Disease Index (OSDI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov